Biomea Fusion (BMEA) Competitors

Biomea Fusion logo
$0.59 +0.06 (+11.02%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$0.57 -0.02 (-2.96%)
As of 11/19/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BMEA vs. ORMP, PEPG, SION, INO, and STRO

Should you buy Biomea Fusion stock or one of its competitors? Biomea Fusion's main competitors and comparable companies include Oramed Pharmaceuticals (ORMP), PepGen (PEPG), Sionna Therapeutics (SION), Inovio Pharmaceuticals (INO), and Sutro Biopharma (STRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biomea Fusion compare to Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Biomea Fusion has a consensus price target of $7.60, indicating a potential upside of 1,191.64%. Given Biomea Fusion's higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Oramed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Biomea Fusion
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Oramed Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market.

In the previous week, Biomea Fusion had 8 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 10 mentions for Biomea Fusion and 2 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.90 beat Biomea Fusion's score of 0.38 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oramed Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biomea Fusion
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oramed Pharmaceuticals' return on equity of -6.97% beat Biomea Fusion's return on equity.

Company Net Margins Return on Equity Return on Assets
Oramed PharmaceuticalsN/A -6.97% -6.01%
Biomea Fusion N/A -223.55%-89.45%

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 10.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oramed Pharmaceuticals has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oramed Pharmaceuticals$2M80.24$64.05M$6.160.60
Biomea FusionN/AN/A-$61.80M-$0.11N/A

Summary

Oramed Pharmaceuticals beats Biomea Fusion on 10 of the 14 factors compared between the two stocks.

How does Biomea Fusion compare to PepGen?

PepGen (NASDAQ:PEPG) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, PepGen had 7 more articles in the media than Biomea Fusion. MarketBeat recorded 17 mentions for PepGen and 10 mentions for Biomea Fusion. PepGen's average media sentiment score of 0.55 beat Biomea Fusion's score of 0.38 indicating that PepGen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PepGen
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Biomea Fusion
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

PepGen has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

PepGen's return on equity of -58.18% beat Biomea Fusion's return on equity.

Company Net Margins Return on Equity Return on Assets
PepGenN/A -58.18% -48.92%
Biomea Fusion N/A -223.55%-89.45%

PepGen currently has a consensus target price of $11.40, indicating a potential upside of 190.08%. Biomea Fusion has a consensus target price of $7.60, indicating a potential upside of 1,191.64%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than PepGen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PepGen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Biomea Fusion
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Biomea Fusion is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PepGenN/AN/A-$89.65M-$1.07N/A
Biomea FusionN/AN/A-$61.80M-$0.11N/A

58.0% of PepGen shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 1.3% of PepGen shares are held by insiders. Comparatively, 10.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Biomea Fusion beats PepGen on 7 of the 13 factors compared between the two stocks.

How does Biomea Fusion compare to Sionna Therapeutics?

Biomea Fusion (NASDAQ:BMEA) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Sionna Therapeutics' return on equity of -39.78% beat Biomea Fusion's return on equity.

Company Net Margins Return on Equity Return on Assets
Biomea FusionN/A -223.55% -89.45%
Sionna Therapeutics N/A -39.78%-37.21%

96.7% of Biomea Fusion shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biomea Fusion has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Biomea Fusion currently has a consensus target price of $7.60, suggesting a potential upside of 1,191.64%. Sionna Therapeutics has a consensus target price of $42.33, suggesting a potential upside of 1,325.36%. Given Sionna Therapeutics' higher possible upside, analysts plainly believe Sionna Therapeutics is more favorable than Biomea Fusion.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomea Fusion
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Sionna Therapeutics
1 Sell rating(s)
11 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Biomea Fusion is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomea FusionN/AN/A-$61.80M-$0.11N/A
Sionna TherapeuticsN/AN/A-$75.27M-$2.44N/A

In the previous week, Biomea Fusion had 10 more articles in the media than Sionna Therapeutics. MarketBeat recorded 10 mentions for Biomea Fusion and 0 mentions for Sionna Therapeutics. Biomea Fusion's average media sentiment score of 0.38 beat Sionna Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media.

Company Overall Sentiment
Biomea Fusion Neutral
Sionna Therapeutics Neutral

Summary

Biomea Fusion beats Sionna Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Biomea Fusion compare to Inovio Pharmaceuticals?

Biomea Fusion (NASDAQ:BMEA) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Biomea Fusion presently has a consensus price target of $7.60, indicating a potential upside of 1,191.64%. Inovio Pharmaceuticals has a consensus price target of $6.33, indicating a potential upside of 270.37%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities research analysts clearly believe Biomea Fusion is more favorable than Inovio Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomea Fusion
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Inovio Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Biomea Fusion's return on equity of -223.55% beat Inovio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Biomea FusionN/A -223.55% -89.45%
Inovio Pharmaceuticals N/A -28,886.30%-75.67%

Biomea Fusion has higher earnings, but lower revenue than Inovio Pharmaceuticals. Biomea Fusion is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomea FusionN/AN/A-$61.80M-$0.11N/A
Inovio Pharmaceuticals$60K3,140.13-$84.95M-$0.54N/A

Biomea Fusion has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Inovio Pharmaceuticals had 6 more articles in the media than Biomea Fusion. MarketBeat recorded 16 mentions for Inovio Pharmaceuticals and 10 mentions for Biomea Fusion. Inovio Pharmaceuticals' average media sentiment score of 0.56 beat Biomea Fusion's score of 0.38 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biomea Fusion
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inovio Pharmaceuticals
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Biomea Fusion beats Inovio Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Biomea Fusion compare to Sutro Biopharma?

Biomea Fusion (NASDAQ:BMEA) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Sutro Biopharma had 7 more articles in the media than Biomea Fusion. MarketBeat recorded 17 mentions for Sutro Biopharma and 10 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.38 beat Sutro Biopharma's score of 0.24 indicating that Biomea Fusion is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biomea Fusion
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sutro Biopharma
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Biomea Fusion has higher earnings, but lower revenue than Sutro Biopharma. Biomea Fusion is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomea FusionN/AN/A-$61.80M-$0.11N/A
Sutro Biopharma$102.48M1.41-$191.09M-$7.17N/A

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biomea Fusion has a net margin of 0.00% compared to Sutro Biopharma's net margin of -344.22%. Sutro Biopharma's return on equity of 0.00% beat Biomea Fusion's return on equity.

Company Net Margins Return on Equity Return on Assets
Biomea FusionN/A -223.55% -89.45%
Sutro Biopharma -344.22%N/A -78.92%

Biomea Fusion has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

Biomea Fusion currently has a consensus target price of $7.60, suggesting a potential upside of 1,191.64%. Sutro Biopharma has a consensus target price of $49.60, suggesting a potential upside of 468.81%. Given Biomea Fusion's higher probable upside, equities research analysts clearly believe Biomea Fusion is more favorable than Sutro Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomea Fusion
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Sutro Biopharma
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00

Summary

Sutro Biopharma beats Biomea Fusion on 10 of the 16 factors compared between the two stocks.

Get Biomea Fusion News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMEA vs. The Competition

MetricBiomea FusionBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$38.52M$3.98B$7.59B$11.70B
Dividend YieldN/A3.64%2.48%4.65%
P/E Ratio-5.3525.7931.9926.76
Price / SalesN/A15.788.405.53
Price / CashN/A22.6520.7221.66
Price / Book5.884.294.423.65
Net Income-$61.80M-$23.99M$3.51B$394.00M
7 Day Performance1.06%-6.11%-5.44%-5.74%
1 Month Performance-20.01%-11.62%-8.62%-9.54%
1 Year Performance-41.16%-4.96%-1.31%-6.71%

Biomea Fusion Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMEA
Biomea Fusion
2.7233 of 5 stars
$0.59
+11.0%
$7.60
+1,191.6%
-46.5%$38.52MN/AN/A34
ORMP
Oramed Pharmaceuticals
2.7558 of 5 stars
$4.00
+3.6%
N/A+48.2%$171.80M$2M0.9713
PEPG
PepGen
3.7918 of 5 stars
$2.39
-3.2%
$11.40
+377.0%
-28.9%$169.69MN/AN/A57
SION
Sionna Therapeutics
1.9781 of 5 stars
$3.57
+8.8%
$42.33
+1,085.8%
-92.3%$168.64MN/AN/A59
INO
Inovio Pharmaceuticals
3.1962 of 5 stars
$1.51
+24.3%
$5.67
+275.3%
-3.9%$167.50M$60KN/A112

Related Companies and Tools


This page (NASDAQ:BMEA) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners